Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C5H4NOS.Zn |
| Molecular Weight | 317.722 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].[O-][N+]1=CC=CC=C1[S-].[O-][N+]2=CC=CC=C2[S-]
InChI
InChIKey=OTPSWLRZXRHDNX-UHFFFAOYSA-L
InChI=1S/2C5H5NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4,8H;/q;;+2/p-2
| Molecular Formula | Zn |
| Molecular Weight | 65.409 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H5NOS |
| Molecular Weight | 127.164 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pyrithione zinc is an antibacterial and antifungal agent developed by scientists in the 1930's. Since then it has been used to treat seborrheic dermatitis of the scalp and other skin conditions such as eczema, athlete's foot, and vitiligo, as well as psoriasis. Because of its antifungal properties, it is commonly found in dandruff shampoo. Products containing pyrithione zinc are available today with and without prescription, and it is the main ingredient in many over-the-counter creams, lotions, soaps, and shampoos. It also has antibacterial properties and is effective against many pathogens from the Streptococcus and Staphylococcus genera. Pyrithione zinc`s other medical applications include treatments of psoriasis, eczema, ringworm, fungus, athletes foot, dry skin, atopic dermatitis, tinea, and vitiligo. Its antifungal effect is thought to derive from its ability to disrupt membrane transport by blocking the proton pump that energizes the transport mechanism.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5705 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26940742 |
0.98 µM [IC50] | ||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22105358 |
|||
Target ID: CHEMBL4261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20473380 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Pyrithione zinc shampoo Approved UsePyrithione zinc shampoo is used for:
Treating and preventing itching, flaking, and scaling of the scalp caused by dandruff or seborrhea (oily, crusting, or scaling skin).
Pyrithione zinc shampoo is an antiseborrheic. It works by slowing the production of skin cells, which helps to reduce flakiness. Launch Date1986 |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/730082/ |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRITHIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.01 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/730082/ |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRITHIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
115 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/730082/ |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
PYRITHIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 % 2 times / week multiple, topical Recommended Dose: 1 %, 2 times / week Route: topical Route: multiple Dose: 1 %, 2 times / week Sources: |
unhealthy, 17–64 |
Disc. AE: Erythema... AEs leading to discontinuation/dose reduction: Erythema (1.25%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Erythema | 1.25% Disc. AE |
1 % 2 times / week multiple, topical Recommended Dose: 1 %, 2 times / week Route: topical Route: multiple Dose: 1 %, 2 times / week Sources: |
unhealthy, 17–64 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Zinc in innate and adaptive tumor immunity. | 2010-11-18 |
|
| Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. | 2010-11-04 |
|
| Novel antifouling agent zinc pyrithione: determination, acute toxicity, and bioaccumulation in marine mussels (Mytilus galloprovincialis). | 2010-11 |
|
| UVB radiation induces an increase in intracellular zinc in human epidermal keratinocytes. | 2010-10 |
|
| Activation of the orphan receptor tyrosine kinase ALK by zinc. | 2010-08-06 |
|
| Dandruff: the most commercially exploited skin disease. | 2010-07-08 |
|
| An integrated imaging approach to the study of oxidative stress generation by mitochondrial dysfunction in living cells. | 2010-07 |
|
| K+ channel openers restore verapamil-inhibited lung fluid resolution and transepithelial ion transport. | 2010-05-27 |
|
| DNA microarray analysis suggests that zinc pyrithione causes iron starvation to the yeast Saccharomyces cerevisiae. | 2010-05 |
|
| Zinc signals promote IL-2-dependent proliferation of T cells. | 2010-05 |
|
| Cellular zinc homeostasis is a regulator in monocyte differentiation of HL-60 cells by 1 alpha,25-dihydroxyvitamin D3. | 2010-05 |
|
| The roles of iPLA2, TRPM8 and TRPA1 in chemically induced cold hypersensitivity. | 2010-01-21 |
|
| Leaching of hydrophobic Cu and Zn from discarded marine antifouling paint residues: evidence for transchelation of metal pyrithiones. | 2009-12 |
|
| Metal ionophores - an emerging class of anticancer drugs. | 2009-11 |
|
| Tracing of intracellular zinc(II) fluorescence flux to monitor cell apoptosis by using FluoZin-3AM. | 2009-10 |
|
| Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. | 2009-10 |
|
| Pyrithione and 8-hydroxyquinolines transport lead across erythrocyte membranes. | 2009-09 |
|
| Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. | 2009-09 |
|
| Molecular mechanism underlying Akt activation in zinc-induced cardioprotection. | 2009-08 |
|
| Rising zinc: a significant cause of ischemic neuronal death in the CA1 region of rat hippocampus. | 2009-08 |
|
| Biofouling growth in cold estuarine waters and evaluation of some chitosan and copper anti-fouling paints. | 2009-07-14 |
|
| Electrospray ionization mass spectrometric observation of ligand exchange of zinc pyrithione with amino acids. | 2009-07 |
|
| Clioquinol and pyrithione activate TRPA1 by increasing intracellular Zn2+. | 2009-05-19 |
|
| Trace metals in antifouling paint particles and their heterogeneous contamination of coastal sediments. | 2009-04 |
|
| Pannexin-1-dependent caspase-1 activation and secretion of IL-1beta is regulated by zinc. | 2009-02 |
|
| 2-(2,3,5,6-Tetra-methyl-benzyl-sulfan-yl)pyridine N-oxide. | 2008-09-20 |
|
| 2-(Mesitylmethylsulfanyl)pyridine N-oxide monohydrate. | 2008-09-17 |
|
| Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta. | 2008-09 |
|
| Aryl-bridged 1-hydroxypyridin-2-one: sensitizer ligands for Eu(III). | 2008-07-21 |
|
| Synthesis and anticancer properties of water-soluble zinc ionophores. | 2008-07-01 |
|
| Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase. | 2008-06 |
|
| In vitro-refolding of a single-chain Fv fragment in the presence of heteroaromatic thiols. | 2008-04-30 |
|
| 2-(Benzyl-sulfan-yl)pyridine N-oxide. | 2008-04-26 |
|
| Insights into Zn2+ homeostasis in neurons from experimental and modeling studies. | 2008-03 |
|
| Poly[ethano-lbis(μ(3)-2-thio-xo-1,2-dihydro-pyridin-1-olato)dilithium(I)]. | 2008-02-08 |
|
| Comparative effects of sodium pyrithione evoked intracellular calcium elevation in rodent and primate ventral horn motor neurons. | 2008-02-01 |
|
| Thioperoxy derivative generated by UV-induced transformation of N-hydroxypyridine-2(1H)-thione isolated in low-temperature matrixes. | 2008-01-17 |
|
| 2,2'-[2,3,5,6-Tetra-methyl-p-phenyl-ene-bis(methyl-enethio)]bis-(pyridine N-oxide). | 2008-01-09 |
|
| Preliminary evaluation of antimicrobial activity of some chemicals on in vitro apple shoots infected by 'Candidatus Phytoplasma mali'. | 2008 |
|
| NADPH-dependent coenzyme Q reductase is the main enzyme responsible for the reduction of non-mitochondrial CoQ in cells. | 2008 |
|
| Synergistic toxic effects of zinc pyrithione and copper to three marine species: Implications on setting appropriate water quality criteria. | 2008 |
|
| Toxicity of four antifouling biocides and their mixtures on the brine shrimp Artemia salina. | 2007-11-15 |
|
| Time-dependent X-ray absorption spectroscopic (XAS) study on the transformation of zinc basic salt into bis(N-oxopyridine-2-thionato) zinc (II). | 2007-11 |
|
| Overexpression of DSCR1 blocks zinc-induced neuronal cell death through the formation of nuclear aggregates. | 2007-08 |
|
| Role of zinc influx via AMPA/kainate receptor activation in metabotropic glutamate receptor-mediated calcium release. | 2007-05-01 |
|
| Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. | 2007-05 |
|
| Opposing effects of ERK and p38 MAP kinases on HeLa cell apoptosis induced by dipyrithione. | 2007-02-28 |
|
| Chemical genetics suggests a critical role for lysyl oxidase in zebrafish notochord morphogenesis. | 2007-01 |
|
| Endogenous zinc in neurological diseases. | 2005-10 |
|
| Flow injection analysis of zinc pyrithione in hair care products on a cobalt phthalocyanine modified screen-printed carbon electrode. | 2004-04-19 |
Sample Use Guides
Shake well before each use.
Wet hair thoroughly. Apply pyrithione zinc shampoo and work into a lather. Rinse thoroughly and repeat.
For best results, use pyrithione zinc shampoo at least 2 times per week or as directed by your doctor. Do not use more often than once daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3882533
Pyrithione zinc had a reversible inhibitory effect on the growth of BHK 21 cells at 0.1 ug/ml, but had a rapid, irreversible inhibitory effect at 1 ug/ml associated with cell rounding and detachment.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:05 GMT 2025
by
admin
on
Mon Mar 31 17:46:05 GMT 2025
|
| Record UNII |
R953O2RHZ5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
||
|
CFR |
21 CFR 358.710
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
||
|
EPA PESTICIDE CODE |
88002
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
||
|
WHO-VATC |
QD11AX12
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1169
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
||
|
WHO-ATC |
D11AX12
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
236-671-3
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
R953O2RHZ5
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
100000085496
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
290409
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
13463-41-7
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
26041
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
DTXSID7026314
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
R953O2RHZ5
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
4498
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
m9377
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL1356238
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
39952
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
C010423
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
SUB10172MIG
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
2295
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
ZINC PYRITHIONE
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
4248
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
DBSALT002737
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
32076
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY | |||
|
C47698
Created by
admin on Mon Mar 31 17:46:05 GMT 2025 , Edited by admin on Mon Mar 31 17:46:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |